Drug updated on 4/17/2024
Dosage Form | Injection (intravenous; 20 mg) |
Drug Class | Hydrolytic lysosomal enzymes |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for treatment of non-central nervous system manifestations of acid sphingomyelinase deficiency (ASMD) in adult and pediatric patients.
Latest News
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Xenpozyme (olipudase alfa-rpcp) prescribing information. | 2023 | Genzyme Corporation, Cambridge, MA |